Given the critical role of TAK1, NF-κB, EGFR and Akt pathways in therapy resistance and tumor progression, agents like DHC that inhibit these pathways could provide a therapeutic advantage, especially in cancers that are refractory to conventional treatments. This evidence concerns the gene EGFR and cancer.